Quarterly ResultMay 6, 2026, 04:53 PM
Geron Q1 Net Loss Narrows to $3.64M; Revenue Jumps 31% to $51.84M
AI Summary
Geron Corporation reported a significant improvement in its first quarter 2026 financial results, with net loss narrowing to $3.64 million, a substantial reduction from $19.84 million in the prior year. Total revenues increased by 31% to $51.84 million, primarily driven by strong product revenue from RYTELO. The company also amended its Pharmakon Loan Agreement, extending the availability of Tranche B and C loans and the make-whole premium date. Ongoing legal proceedings related to securities class action and derivative lawsuits continue.
Key Highlights
- Net loss for Q1 2026 narrowed to $3.64 million from $19.84 million in Q1 2025.
- Total revenues increased 31% to $51.84 million in Q1 2026 from $39.60 million in Q1 2025.
- Product revenue, net, rose to $51.77 million in Q1 2026 from $39.44 million in Q1 2025.
- Basic and diluted net loss per share improved to $(0.01) in Q1 2026 from $(0.03) in Q1 2025.
- Cash and cash equivalents were $68.90 million as of March 31, 2026.
- Marketable securities totaled $243.51 million as of March 31, 2026.
- Net cash used in operating activities increased to $62.91 million in Q1 2026 from $47.98 million in Q1 2025.
- Pharmakon Loan Agreement amended to extend Tranche B/C loan request date to July 30, 2026.
Price Impact
More from GERN